Another possible explanation for achieving only a moderate beneficial effect by TLR4 inhibition claims that neuroinflammation is only a part of the disease process in ALS, and that the neurodegenerative process is relentlessly progressing even without the added damage induced by the accompanying inflammatory response. Here, TLR4 is linked to amyotrophic lateral sclerosis.